Back to results
US 2003/0113743 A1Published application
Method for detection of micrometastatic prostate cancer
AssigneeBaylor College of Medicine, Hybritech Incorporated
InventorsKevin M. Slawin, Donald J. Tindall, Charles Y.F. Young
Life of this patent
Estimating the term…
Abstract
Prostate cancer is detected by determining the presence of hK2 RNA in a physiological sample.
Claims53
A diagnostic method for detecting hK2 DNA comprising:
- (a) contacting an amount of DNA obtained by reverse transcription of RNA from a human physiological sample which comprises cells suspected of containing hK2 RNA with an amount of at least two oligonucleotides under conditions effective to amplify the DNA by a polymerase chain reaction so as to yield an amount of amplified hK2 DNA, wherein the conditions are effective to amplify the amount of DNA obtained by reverse transcription of RNA from at least one cell containing hK2 in a sample which comprises at least about 107 to about 109 cells;
- and
- (b) detecting the presence of the amplified hK2 DNA.
A method for detecting metastatic prostate cancer in a human, comprising:
- (a) contacting an amount of DNA obtained by reverse transcription of RNA from a human physiological sample which comprises cells suspected of containing hK2 RNA with an amount of at least two oligonucleotides under conditions effective to amplify the DNA by a polymerase chain reaction so as to yield an amount of amplified hK2 DNA, wherein the conditions are effective to amplify the amount of DNA obtained by reverse transcription of RNA from at least one cell containing hK2 in a sample which comprises at least about 107 to about 109 cells;
- (b) detecting the presence of the amplified hK2 DNA, wherein the presence of hK2 DNA is indicative of the presence of metastatic prostate cancer in said human.
A diagnostic method for detecting hK2 RNA comprising:
- (a) extracting RNA from a physiological sample obtained from a human, wherein the sample comprises cells;
- (b) reverse transcribing the extracted RNA to yield DNA;
- (c) contacting the DNA with an amount of at least two oligonucleotides under conditions effective to amplify the DNA by polymerase chain reaction so as to yield an amount amplified hK2 DNA, wherein the conditions are effective to amplify the amount of DNA obtained by reverse transcription of RNA from at least one cell containing hK2 in a sample which comprises at least about 107 to about 109 cells;
- and
- (d) detecting the presence of the amplified hK2 DNA, wherein the presence of the amplified hK2 DNA is indicative of metastatic prostate cancer in the human.
2 more elements
A method for monitoring the progression of prostate cancer, comprising:
- (a) contacting an amount of DNA obtained by reverse transcription of RNA from a physiological sample obtained from a human afflicted with prostate cancer with an amount of at least two oligonucleotides under conditions effective to amplify the DNA by a polymerase chain reaction so as to yield an amount of amplified hK2 DNA, wherein the physiological sample comprises cells, and wherein the conditions are effective to amplify an amount of DNA obtained by reverse transcription of RNA from at least one cell containing hK2 in a sample which comprises at least about 107 to about 109 cells;
- (b) detecting or determining the amount of the amplified hK2 DNA;
- (c) repeating steps (a) and (b) at a point later in time;
- and
- (d) comparing the result of step (b) with the result of step (c), wherein an increase in the amount of hK2 DNA is indicative of the progression of prostate cancer in said human.
2 more elements
A method for pathologically staging prostate cancer, comprising:
- (a) contacting an amount of DNA obtained by reverse transcription of RNA from a physiological sample obtained from a human afflicted with prostate cancer with an amount of at least two oligonucleotides under conditions effective to amplify the DNA by a polymerase chain reaction so as to yield an amount of amplified hK2 DNA, wherein the physiological sample comprises cells, and wherein the conditions are effective to amplify an amount of DNA obtained by reverse transcription of RNA from at least one cell containing hK2 in a sample which comprises at least about 107 to about 109 cells;
- and
- (b) detecting or determining the presence or amount of the amplified hK2 DNA, wherein the presence or amount of amplified hK2 DNA is indicative of the pathological stage of the prostate cancer.
An oligonucleotide which consists of at least about 7-50 nucleotides, and which has at least about 80% identity to, or has complementarity to, a nucleotide sequence comprising SEQ ID NO:27.
An oligonucleotide which consists of at least about 7-50 nucleotides, and which has at least about 80% identity to, or has complementarity to, a nucleotide sequence comprising SEQ ID NO:28.
A diagnostic method for detecting hK2 DNA comprising:
- (a) contacting an amount of DNA obtained by reverse transcription of RNA from a human physiological sample which comprises cells suspected of containing hK2 RNA, with an amount of at least two oligonucleotides under conditions effective to amplify the DNA by a polymerase chain reaction so as to yield an amount of amplified hK2 DNA, wherein at least one oligonucleotide is an hK2-specific oligonucleotide;
- and
- (b) detecting the presence of the amplified hK2 DNA.
A method for detecting metastatic prostate cancer in a human, comprising:
- (a) contacting an amount of DNA obtained by reverse transcription of RNA from a human physiological sample which comprises cells suspected of containing hK2 RNA, with an amount of at least two oligonucleotides under conditions effective to amplify the DNA by a polymerase chain reaction so as to yield an amount of amplified hK2 DNA, wherein at least one oligonucleotide is an hK2-specific oligonucleotide;
- and
- (b) detecting the presence of the amplified hK2 DNA, wherein the presence of hK2 DNA is indicative of the presence of metastatic prostate cancer in said human.
A diagnostic method for detecting hK2 RNA comprising:
- (a) extracting RNA from a physiological sample obtained from a human;
- (b) reverse transcribing the extracted RNA to yield DNA;
- (c) contacting the DNA with an amount of at least two oligonucleotides under conditions effective to amplify the DNA by polymerase chain reaction so as to yield an amount amplified hK2 DNA, wherein at least one oligonucleotide is an hK2-specific oligonucleotide;
- and
- (d) detecting the presence of the amplified hK2 DNA, wherein the presence of the amplified hK2 DNA is indicative of metastatic prostate cancer in the human.
2 more elements
A method for monitoring the progression of prostate cancer, comprising:
- (a) contacting an amount of DNA obtained by reverse transcription of RNA from a physiological sample obtained from a human afflicted with prostate cancer with an amount of at least two oligonucleotides under conditions effective to amplify the DNA by a polymerase chain reaction so as to yield an amount of amplified hK2 DNA, wherein at least one oligonucleotide is an hK2-specific oligonucleotide;
- (b) detecting or determining the amount of the amplified hK2 DNA;
- (c) repeating steps (a) and (b) at a point later in time;
- and
- (d) comparing the result of step (b) with the result of step (c), wherein an increase in the amount of hK2 DNA is indicative of the progression of prostate cancer in said human.
2 more elements
A method for pathologically staging prostate cancer, comprising:
- (a) contacting an amount of DNA obtained by reverse transcription of RNA from a physiological sample obtained from a human afflicted with prostate cancer with an amount of at least two oligonucleotides under conditions effective to amplify the DNA by a polymerase chain reaction so as to yield an amount of amplified hK2 DNA, wherein at least one oligonucleotide is an hK2-specific oligonucleotide;
- and
- (b) detecting or determining the presence or amount of the amplified hK2 DNA, wherein the presence or amount of amplified hK2 DNA is indicative of the pathological stage of the prostate cancer.
Dependencies are inferred from the claim text.